Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: Two case reports and a review of the literature

Transfusion

Volumn 53, Issue 7, 2013, Pages 1586-1593

  Yilmaz, Murvet ^a   Eskazan, Ahmet Emre ^a   Unsal, Abdulkadir ^a   Taninmis, Hakan ^a   Kara, Ekrem ^a   Cetiner, Mustafa ^a   Ferhanoglu, Burhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; CREATININE; CYCLOSPORIN A; IMMUNOGLOBULIN G; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY FAILURE; MALE; MEDICAL HISTORY; PLASMAPHERESIS; PROPHYLAXIS; RECURRENT DISEASE; RELAPSE; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

EID: 84880229426     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03944.x     Document Type: Article

References (45)

1. Moschcowitz E,. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Arch Intern Med 1925; 36: 89-93.
2. Sadler JE, Moake JL, Miyata T, George JN,. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004; 407-423.
3. Tsai HM,. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-1081.
4. Crowther MA, George JN,. Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med 2008; 75: 369-375.
5. Rock GA,. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109: 496-507.
6. O'Connor NT, O'Shea MJ, Hill LF,. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 490.
7. Durand JM, Lefevre P, Kaplanski G, Telle H, Soubeyrand J,. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 977-978.
8. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J,. Ineffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 234.
9. Udvardy M, Rak K,. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet 1990; 336: 1508-1509.
10. Gutterman LA, Kloster B, Tsai HM,. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002; 28: 385-391.
11. Crowther MA, Heddle N, Hayward CP, Warkentin T, Kelton JG,. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125: 294-296.
12. George JN,. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl 2009;(112): S52-54.
13. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A,; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822.
14. George JN, Vesely SK, Terrell DR,. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-67.
15. Willis MS, Bandarenko N,. Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Semin Thromb Hemost 2005; 31: 700-708.
16. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
17. Novartis Pharmaceuticals Corporation. Sandimmune® (cyclosporine capsules, USP) Prescribing Information. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2012.
18. Kahan BD,. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
19. Medina PJ, Sipols JM, George JN,. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286-293.
20. Elliott MA, Nichols WL Jr, Plumhoff EA, Ansell SM, Dispenzieri A, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Tefferi A, Litzow M,. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421-430.
21. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V,. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 2457-2466.
22. Cataland SR, Jin M, Ferketich AK, Kennedy MS, Kraut EH, George JN, Wu HM,. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 146-149.
23. Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM,. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007; 139: 486-493.
24. Cataland SR, Jin M, Zheng XL, George JN, Wu HM,. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1162-1164.
25. Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM,. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83: 911-915.
26. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE,. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-68.
27. Mannucci PM, Peyvandi F,. TTP and ADAMTS13: when is testing appropriate? Hematology Am Soc Hematol Educ Program 2007; 121-126.
28. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE,. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
29. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM,. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-658.
30. Nosari A, Redaelli R, Caimi TM, Mostarda G, Morra E,. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura. Am J Hematol 2009; 84: 313-314.
31. Kierdorf H, Maurin N, Heintz B,. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993; 118: 987-988.
32. Nosari A, Bernuzzi P, Corneo R, Pungolino E, Muti G, Rossi V, Morra E,. Late response to cyclosporine in refractory thrombotic thrombocytopenic purpura. Int J Hematol 2002; 76: 284-286.
33. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS,. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902.
34. Mauro M, Zlatopolskiy A, Raife TJ, Laurence J,. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol 2004; 124: 200-210.
35. Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, Remuzzi G,. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443-452.
36. George JN,. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
37. Pasquale D, Vidhya R, DaSilva K, Tsan MF, Lansing L, Chikkappa G,. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. Am J Hematol 1998; 57: 57-61.
38. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP,. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.
39. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM,. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-795.
40. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, Daina E, Perseghin P, Scheiflinger F, Fakhouri F, Grünfeld JP, Pogliani E, Remuzzi G,. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005; 106: 925-928.
41. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC, Skikne BS, Sahud MA,. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005; 84: 232-235.
42. Montoya RC, Poiesz BJ,. Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature. Blood Coagul Fibrinolysis 2012; 23: 338-341.
43. Balogun RA, Sahadevan M, Sevigny J, Kaplan AA,. Impact of therapeutic plasma exchange on cyclosporine kinetics during membrane-based lipid apheresis. Am J Kidney Dis 2001; 37: 1286-1289.
44. Hull MJ, Eichbaum QG,. Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006; 4: 210-214.
45. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA,. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-1208.